Zydus Lifesciences Overview
- Year Founded
-
1952
- Status
-
Public
- Employees
-
29,475
- Stock Symbol
-
532321
- Investments
-
30
- Share Price
-
$10.60
- (As of Wednesday Closing)
Zydus Lifesciences General Information
Description
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are; Pharmaceuticals which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States followed by India, and other countries.
Contact Information
Website
www.zyduslife.comCorporate Office
- Zydus Corporate Park, Scheme Number. 63, Khoraj (Gandhinagar), 536
- Sarkhej - Gandhinagar Highway, Near Vaishnodevi Circle
- Ahmedabad, Gujarat 382481
- India
Corporate Office
- Zydus Corporate Park, Scheme Number. 63, Khoraj (Gandhinagar), 536
- Sarkhej - Gandhinagar Highway, Near Vaishnodevi Circle
- Ahmedabad, Gujarat 382481
- India
Zydus Lifesciences Stock Performance
As of 26-Mar-2025, Zydus Lifesciences’s stock price is $10.60. Its current market cap is $10.7B with 1.01B shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.60 | $10.61 | $9.83 - $15.76 | $10.7B | 1.01B | 45.7K | $0.54 |
Zydus Lifesciences Financials Summary
As of 31-Dec-2024, Zydus Lifesciences has a trailing 12-month revenue of $2.59B.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 |
|---|---|---|---|---|
| EV | 11,337,866 | 12,175,412 | 6,403,326 | 5,005,350 |
| Revenue | 2,587,346 | 2,297,675 | 2,101,899 | 1,990,080 |
| EBITDA | 806,057 | 663,181 | 418,716 | 485,830 |
| Net Income | 542,195 | 466,203 | 244,129 | 602,261 |
| Total Assets | 3,511,161 | 3,137,160 | 3,665,571 | |
| Total Debt | 0 | 96,434 | 145,540 | 556,639 |
Zydus Lifesciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zydus Lifesciences Comparisons
Industry
Financing
Details
Zydus Lifesciences Competitors (36)
One of Zydus Lifesciences’s 36 competitors is Torrent Pharmaceuticals, a Corporation company based in Ahmedabad, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals | Corporation | Ahmedabad, India | ||||
| Mankind Pharma | Formerly PE-Backed | New Delhi, India | ||||
| Ajanta Pharma | Corporation | Mumbai, India | ||||
| Glenmark Pharmaceuticals | Corporation | Mumbai, India | ||||
| Jubilant Pharmova | Corporation | Noida, India |
Zydus Lifesciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Zydus Lifesciences Patents
Zydus Lifesciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250051295-A1 | Process for the preparation of mirabegron free from genotoxic impurities | Pending | 07-Aug-2023 | ||
| US-20250034095-A1 | New process for preparation of aficamten | Pending | 10-Jul-2023 | ||
| US-20240423993-A1 | Amorphous form of resmetirom and process for preparation thereof | Pending | 23-Jun-2023 | ||
| US-20240316041-A1 | Process for the preparation of sitagliptin free from genotoxic impurities | Pending | 03-Mar-2023 | ||
| AU-2023285400-A1 | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management | Pending | 08-Jun-2022 | A61K9/0019 |
Zydus Lifesciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Zydus Lifesciences Investments & Acquisitions (30)
Zydus Lifesciences’s most recent deal was a Merger/Acquisition with Amplitude Surgical for . The deal was made on 11-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Amplitude Surgical | 11-Mar-2025 | Merger/Acquisition | Therapeutic Devices | ||
| Sterling Biotech ( API business ) | 17-Sep-2024 | Merger/Acquisition | Pharmaceuticals | ||
| Sterling Biotech | 29-Aug-2024 | Merger/Acquisition | Pharmaceuticals | ||
| Mylab Discovery Solutions | 23-Jun-2023 | Secondary Transaction - Private | Diagnostic Equipment | ||
| Watson Laboratories (Active Pharmaceutical Ingredient Assets in India) | 01-Dec-2022 | Corporate Asset Purchase | Buildings and Property |
Zydus Lifesciences ESG
Risk Overview
Risk Rating
Updated April, 13, 2024
29.08 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Pharmaceuticals
Subindustry
of 421
Rank
Percentile
Zydus Lifesciences Exits (3)
Zydus Lifesciences’s most recent exit was on 27-Jul-2011 from Bremer Pharma. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Bremer Pharma | 27-Jul-2011 | Completed |
|
||
| Zenex Animal Health | 14-May-2007 | Completed |
|
||
| Zenex Animal Health | 01-Jan-2000 | Joint Venture | Completed |
|
Zydus Lifesciences Affiliates
Subsidiaries (7)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Zynext Ventures | Pennington, NJ | 2023 | |
| Sentynl Therapeutics | Solana Beach, CA | 2011 | |
| Laboratorios Combix | Madrid, Spain | 2006 | |
| Etna Biotech | Catania, Italy | 2001 | |
| The Kraft Heinz Company (India Division) | Mumbai, India | 1994 |
Zydus Lifesciences FAQs
-
When was Zydus Lifesciences founded?
Zydus Lifesciences was founded in 1952.
-
Where is Zydus Lifesciences headquartered?
Zydus Lifesciences is headquartered in Ahmedabad, India.
-
What is the size of Zydus Lifesciences?
Zydus Lifesciences has 29,475 total employees.
-
What industry is Zydus Lifesciences in?
Zydus Lifesciences’s primary industry is Pharmaceuticals.
-
Is Zydus Lifesciences a private or public company?
Zydus Lifesciences is a Public company.
-
What is Zydus Lifesciences’s stock symbol?
The ticker symbol for Zydus Lifesciences is 532321.
-
What is the current stock price of Zydus Lifesciences?
As of 26-Mar-2025 the stock price of Zydus Lifesciences is $10.60.
-
What is the current market cap of Zydus Lifesciences?
The current market capitalization of Zydus Lifesciences is $10.7B.
-
What is Zydus Lifesciences’s current revenue?
The trailing twelve month revenue for Zydus Lifesciences is $2.59B.
-
Who are Zydus Lifesciences’s competitors?
Torrent Pharmaceuticals, Mankind Pharma, Ajanta Pharma, Glenmark Pharmaceuticals, and Jubilant Pharmova are some of the 36 competitors of Zydus Lifesciences.
-
What is Zydus Lifesciences’s annual earnings per share (EPS)?
Zydus Lifesciences’s EPS for 12 months was $0.54.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
